Purdue Pharmaceuticals, L.P.
Headquarters
One Stamford Forum
Stamford
Connecticut
06901-3431
United States
Tel: 203-588-8000
Fax: 203-588-8850
Website: http://www.purduepharma.com/
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
232 articles about Purdue Pharmaceuticals, L.P.
-
That announcement is a big change in the way Purdue has aggressively marketed OxyContin in the past.
-
Purdue Pharma L.P. Awards Grants to Further Research on the Assessment of Chronic Pain
1/31/2018
Purdue Pharma, L.P. today announced the funding of three grants for investigator-initiated research on developing clinically relevant and useful tools to assist in the assessment of chronic pain, including research on Virtual Reality (VR) technology to assess chronic pain intensity; electroencephalograph (EEG) alpha activity as an objective measurement of pain; and the relationship between pain and attentional processes and cognitive functioning.
-
Eisai and Purdue Pharma L.P. Presented Lemborexant Data From Research Studies at ACNP Annual Meeting
12/7/2017
The Asakura et al. poster presentation reported a non-clinical study demonstrating differences in lemborexant abuse liability when compared to a currently marketed insomnia treatment, suvorexant.
-
A number of biopharma companies are making strides in developing non-opioid pain killers or opioids that are more difficult to abuse.
-
Purdue Pharma L.P. Announces Strategic Investment in Oncology R&D
11/14/2017
Purdue Pharma, L.P. today announced completion of significant oncology related investments as part of its ongoing efforts to diversify its scientific research into areas of high unmet medical need.
-
Purdue Pharma Joins the Prescription Drug Safety Network
11/1/2017
The course includes interactive sessions and self-guided activities to empower students with knowledge, skills, and strategies to help prevent prescription drug misuse and abuse.
-
Shionogi And Purdue Pharma L.P. Announce U.S. Availability Of Symproic® (Naldemedine) For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-Cancer Pain
10/12/2017
-
Purdue Pharma L.P. And Geisinger Announce First Patient Enrollment In Clinical Trial Assessing Effect Of Wearable Health Technology On Chronic Pain Patients
10/5/2017
-
BioDelivery Signs Exclusive Agreement With Purdue Pharma L.P. (Canada) For The Licensing And Distribution Rights Of Belbuca In Canada
7/12/2017
-
National Sheriffs’ Association And Purdue Pharma L.P. Announce Additional Funding For Life-Saving Opioid Overdose Initiative
6/26/2017
-
Dr. Craig Landau Appointed President And CEO Purdue Pharma L.P.
6/22/2017
-
Ohio Sues Purdue Pharma L.P. Over Oxycontin’s Deadly Impact
6/1/2017
-
Purdue Pharma L.P. Names Josie Martin Head Of Corporate Affairs & Communications
4/24/2017
-
Purdue Pharma L.P. Announces Hire Of Carrie Chomiak To Lead Over-The-Counter Franchise
4/21/2017
-
Intellipharmaceutics Announces Patent Litigation By Purdue Pharma L.P. Against Its Rexista Abuse-Deterrent Extended-Release Oxycodone
4/10/2017
-
Purdue Pharma L.P., Project Lazarus And Safe Kids NC Partner To Improve Public Health Outcomes In North Carolina Through The North Carolina Disposal Initiative
4/5/2017
-
Senator Launches Investigation Into Top Opioid Makers—Purdue Pharma L.P., Janssen/Johnson & Johnson, INSYS, Mylan And Depomed
3/29/2017
-
Purdue Pharma L.P. Highlights Research From Multiple Studies At AMCP Managed Care & Specialty Pharma Annual Meeting 2017
3/29/2017
-
INSYS Names Purdue Pharma L.P. Exec As New CEO, Effective April 17
3/27/2017
-
Purdue Pharma L.P. Led Collaborative Assessment Identifies Alarming Number Of Errors In Commonly Used Online Drug Information Compendia
3/1/2016